Market Signal Briefing

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies—when compared to an external control—would be adequate to support a BLA submission, notwithstanding the prespecified protocols and statistical analysis plans previously shared with the agency. The Company further admitted that, while it planned to urgently engage with the FDA, the timing of any BLA submission for AMT-130 was now unclear. This disclosure revealed the falsity of Defendants' prior representations that AMT-130 was on a near-term path toward accelerated approval.

On this news, uniQure's ordinary share price fell $33.40 per share, or more than 49%, declining from a close of $67.69 on October 31, 2025 to $34.29 on November 3, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding uniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the uniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PayPal To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in PayPal between February 25, 2025 and February 2, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PayPal Holdings, Inc. ("PayPal" or the "Company") (NASAQ: PYPL) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of PayPal's salesforce; notably, that it was not truly equipped to execute on the Company's perceived growth potential and were "too optimistic" as to how easily and expeditiously its staff could change customer adoption. Such statements absent these material facts caused Plaintiff and other shareholders to purchase PayPal's securities at artificially inflated prices.

On February 3, 2026, PayPal announced its fourth quarter and full year 2025 financial results. Among other items, PayPal announced weaker-than-expected fourth quarter earnings and revenue. Separately, PayPal announced the departure of Alex Chriss as the Company's Chief Executive Officer.

On this news, PayPal's stock price fell $10.63 per share, or 20.31%, to close at $41.70 per share on February 3, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding PayPal's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the PayPal class action, go to www.faruqilaw.com/PYPL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In NuScale To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in NuScale between May 13, 2025 and November 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NuScale Power Corporation ("NuScale" or the "Company") (NYSE: SMR) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ENTRA1 had never built, financed, or operated any significant projects – let alone projects in the highly technical and complicated field of nuclear power generation – during its entire operating history; (2) NuScale had entrusted its commercialization, distribution, and deployment of its NPMs and hundreds of millions of dollars of NuScale capital to an entity that lacked any significant prior experience owning, financing, or operating nuclear energy generation facilities; (3) the purported experience and qualifications attributed to ENTRA1 by defendants during the class period in fact referred to the purported experience and qualifications of the principals of the Habboush Group, a distinct entity without significant experience in the field of nuclear power generation; and (4) as a result, NuScale's commercialization strategy was exposed to material, undisclosed risks of failure, delays, regulatory challenges, or other negative setbacks.

On November 6, 2025, NuScale surprised investors by revealing that the Company's general and administrative expenses had ballooned more than 3,000% to $519 million during its third fiscal quarter, up from $17 million in the prior year period, due largely to NuScale's payment of $495 million to ENTRA1 for its TVA agreement. As a result, NuScale's quarterly net loss skyrocketed to $532 million, up from $46 million in the prior year period.

On this news, the price of NuScale Class A shares declined more than 12% over a two-day trading period, from approximately $32 per share on November 6, 2025 to approximately $28 per share on November 10, 2025. The price of NuScale Class A stock continued to fall in subsequent days, dropping to a low of just $17 per share by November 21, 2025 – more than 70% below the class period high of more than $57 per share.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding NuScale's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the NuScale Power Corporation class action, go to www.faruqilaw.com/SMR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

3.64K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© H_Ko / Shutterstock.com

The stock market has been roiled lately, with a sharp sell-off hammering tech stocks in particular. Software and semiconductor names have taken the brunt of the pain, sending the Nasdaq-100 down more than 8% — a steeper drop than the S&P 500’s roughly 7% decline. 

It feels like a blanket statement at first glance: tech is getting crushed across the board. But that narrative misses the outliers. Some companies are proving remarkably resilient, shrugging off the broader gloom and delivering eye-popping gains. Western Digital (NASDAQ:WDC | WDC Price Prediction) stands out as one of them. The storage giant is up over 59% year-to-date, making it the top performer in the Nasdaq-100. Yet it has given back almost 14% from the all-time high it hit earlier this month. 

The big question for investors is whether Western Digital can regain its momentum and keep powering higher.

The AI Storage Supercycle Is Just Getting Started Western Digital’s surge isn’t a fluke — it’s rooted in a structural shift that’s reshaping the data economy. After spinning off its flash-memory business into Sandisk (NASDAQ:SNDK), another high-flying stock that has taken a breather, the company has become a pure-play leader in high-capacity hard disk drives (HDDs), the workhorse storage solution for massive AI workloads. 

Hyperscale cloud providers and data-center operators are scrambling for capacity to handle the exploding volume of training data, inference archives, and long-term “data lakes.” Western Digital’s nearline HDDs deliver the perfect mix of scale, reliability, and low cost per terabyte that these customers crave. Demand has been so intense that the company’s entire 2026 production capacity is already sold out, with firm purchase orders locked in from its top clients extending into 2027 and even 2028. That visibility has translated into stronger pricing power and margin expansion. 

Recent quarterly results underscored the momentum, with revenue jumping solidly year-over-year, earnings beating expectations, and management highlighting multi-year contracts that remove much of the cyclical uncertainty that once plagued the sector. Investors who spotted this AI-driven re-rating early have been rewarded handsomely.

Why the Stock Has Pulled Back From Its Highs Even the strongest stories can hit temporary speed bumps. Western Digital touched an all-time high near $320 in mid-March before sliding roughly 14% amid the wider tech-sector sell-off. Part of it is classic “sell the news” dynamics — investors locked in gains after a blistering run that saw the stock more than quintuple over the past year. 

Broader market jitters around interest rates, geopolitical tensions, and profit-taking in the Magnificent Seven names added fuel to the retreat. Some light insider selling and digestion of the post-earnings rally also played a role. Importantly, none of this reflects any deterioration in the underlying business. Production remains fully booked, customer commitments are rock-solid, and the AI tailwind shows no signs of fading. The pullback looks more like a healthy breather than a fundamental reversal.

Wall Street Remains Bullish With Rising Price Targets Analysts have taken notice of Western Digital’s transformation and are increasingly upbeat. The consensus rating sits at Moderate Buy to Strong Buy, with the majority of the 24-plus firms covering the stock issuing Buy recommendations. Recent notes highlight the structural demand shift and the company’s disciplined execution. 

Cantor Fitzgerald raised its target to $420, citing the multi-year visibility and margin upside. Mizuho moved to $340, Morgan Stanley to $369, and Wells Fargo lifted its call to the mid-$300s range after the latest investor presentations. While the street-wide average target sits around $265 to $330 per share, several high-conviction calls now stretch toward $440. The message is consistent: The AI storage supercycle creates a multi-year runway that justifies a premium valuation for a company that has already proven it can deliver.

Key Takeaway Western Digital’s high-capacity HDDs are in white-hot demand, with supply already outstripped for 2026 and long-term contracts ensuring tight conditions well beyond. There is no let-up in sight — the AI data explosion is structural, not cyclical. That dynamic points to sustained pricing power, robust revenue growth, and expanding margins for years to come. 

For investors, the recent pullback from the all-time high isn’t a warning sign, but rather an attractive entry point into a stock that has already proven itself as the Nasdaq-100’s standout performer. Those who buy the dip today could be well-positioned to ride the next leg of the AI infrastructure boom higher.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On December 16, 2025, Nektar issued a press release "announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell (Treg) proliferator." The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate.

On this news, Nektar's stock price fell $4.14 per share, or 7.77%, to close at $49.16 per share on December 16, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Nektar's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Nektar Therapeutics class action, go to www.faruqilaw.com/NKTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gemini To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Gemini (a) Gemini Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about September 12, 2025 (the "IPO" or "Offering"); (b) and/or Gemini securities between September 12, 2025 and February 17, 2026, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gemini Space Station, Inc. ("Gemini" or the "Company") (NASDAQ: GEMI) and reminds investors of the May 18, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Gemini had overstated the viability of its core business as a crypto platform; (2) Gemini had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (3) accordingly, Gemini's post-IPO financial and business prospects were overstated; (4) all of the foregoing raised a non-speculative risk that Gemini was poised for an expensive and disruptive restructuring; and (5) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and misleading at all relevant times.

On September 15, 2025, Gemini filed the prospectus for the IPO on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (together, the "Offering Documents").

Pursuant to the Offering Documents, Gemini issued 15,178,572 shares of the Company's Class A common stock to the public at the Offering price of $28.00 per share for proceeds, before expenses, of $398,437,515 to the Company.

On December 10, 2025, Gemini announced that it would launch a prediction market and offer event contracts to its U.S. customers. At this time, however, the Defendants gave no indication that the Company was poised for an abrupt corporate pivot to a prediction-market-centric business model.

The truth began to emerge on February 5, 2026, when Gemini filed a Regulation FD disclosure on Form 8-K with the SEC, announcing the publication of a blog post authored by Defendants Tyler and Cameron Winklevoss. In this blog post, the Winklevoss brothers announced a corporate pivot to "Gemini 2.0", describing three dramatic changes to Gemini's operations: (1) Gemini's prediction market would be "more front and center in our experience"; (2) Gemini would reduce its workforce by 25%; and (3) Gemini would exit the United Kingdom, European Union, and Australian markets.

On this news, Gemini's Class A common stock price fell $0.64 per share, or 8.72%, to close at $6.70 per share per share on February 5, 2026.

Then, on February 17, 2026, Gemini issued a Current Report on Form 8-K, announcing the departure of Defendant Marshall Beard, its former Chief Operating Officer ("COO"), Defendant Dan Chen, its former Chief Financial Officer ("CFO"), and Tyler Meade, Gemini's former Chief Legal Officer. The Company also offered "preliminary unaudited estimates" of its financial results for the fiscal year ended December 31, 2025, including net revenue of $165 million to $175 million and operating expenses of $520 million to $530 million, an increase of approximately 40% from the previous fiscal year.

On this news, Gemini's stock price fell $0.975 per share, or 12.9%, to close at $6.585 per share on February 17, 2026.

On or after February 17, 2026, Defendants updated the live version of the Winklevoss brothers' blog post referenced above, adding language that explicitly tied Gemini's restructuring to the departure of Defendant Chen, Defendant Beard, and Tyler Meade from the Company.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Gemini's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Gemini Space Station class action, go to www.faruqilaw.com/GEMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose true state of Boston Scientific's U.S. EP segment; notably, that management was aware that the segment's growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to Defendants' statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026.

On February 4, 2026, Boston Scientific published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and assertions they "have a very good understanding of what competition we will face and in what time frame."

On this news, Boston Scientific's stock price fell $16.12, or 17.6%, to close at $75.50 per share on February 4, 2026, thereby injuring investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Boston Scientific's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Boston Scientific class action, go to www.faruqilaw.com/BSX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Artificial intelligence (AI) stocks have struggled in recent months, upset by a variety of elements. Investors have worried about the fast pace of AI spending, any negative economic data, and geopolitical turmoil, such as the war in Iran. These concerns have weighed on investors' appetite for growth stocks -- the stocks most vulnerable to such problems.

Against this backdrop, one stock in particular has seemed to drop out of favor. It's a company that's delivered explosive earnings growth, has seen its stock soar in the quadruple digits in recent years, and is well positioned for more growth.

The market is punishing this AI stock... but history says that's a mistake.

Image source: Getty Images.

Game-changing technology The stock I'm referring to is Palantir Technologies (PLTR 3.05%), a company that sells AI-driven software to governments and commercial customers. Palantir's software helps them aggregate and analyze their data, then use the findings to make better decisions, develop new processes, or even innovate. It's been a game changer for many, and word has gotten around -- that's spurred soaring demand that's continued quarter after quarter.

And the result has been earnings growth, with revenue and profit on the rise in both the commercial and government businesses. Palantir is particularly popular these days because it helps customers almost effortlessly apply AI to their situations and generate impressive results.

Today's Change

(

-3.05

%) $

-4.50

Current Price

$

143.06

Now, let's consider Palantir's stock performance. The stock has dropped about 20% over the past three months. The headwinds I mentioned above surely have held it back, but another element may also be playing a significant role, and that's valuation. Though Palantir's has come down, it remains at high levels.

A look at history A look at history shows us this isn't the first time that Palantir's valuation has fluctuated. In fact, in the past, every time it's dipped, the stock has gone on to gain -- and many times, gains have been significant.

PLTR PE Ratio (Forward) data by YCharts

Regarding valuation, it's important to note that yes, Palantir's valuation today is high, but this measure only considers earnings estimates a year from now -- it doesn't consider earnings potential years down the road. So, while the stock surely isn't the best bet for investors looking for value stocks, it could be an excellent buy for investors focused on growth.

Today, the market is punishing Palantir, and this may make you hesitate to buy. But history shows us that this player has been through similar periods and each time has gone on to advance. All of this means that avoiding Palantir might be a mistake if you're a growth investor -- instead, now may be the perfect time to get in on this AI winner.

Nobody who built an artificial intelligence-heavy portfolio during the hype years of 2024 and 2025 was thinking about oil prices, a potential war in the Middle East, or a Federal Reserve that refuses to cut rates. But here we are. Artificial intelligence (AI) stocks are largely selling off, and investors are anxiously checking headlines for what is next.

Let's look at what's actually happening. Once you understand it, you can better think about how to protect your portfolio. This isn't just the generic "rotate to defensive stock" advice you'll find everywhere else.

Image source: Getty Images.

Conflict in the Middle East escalates, hitting the world economy On Feb. 28, 2026, U.S. and Israeli military operations against Iran effectively closed the Strait of Hormuz. That's because the Iranian Revolutionary Guard Corps warned the world that the waterway was unsafe for commercial navigation. Tanker traffic fell roughly 70%. Oil, which was trading around $65 a barrel, quickly moved toward $100 a barrel.

Two weeks later, the Federal Reserve held interest rates at 3.5%-3.75% by an 11-1 vote, and explicitly cited the Middle East situation as the reason for its wait-and-see posture. Fed Chair Jerome Powell acknowledged surging oil prices as a near-term inflation risk. The International Energy Agency (IEA) released strategic reserves, but experts estimated that the action would only buy roughly 16–22 days of supply. The U.S. also released a portion of its strategic reserves to help stabilize prices.

Market volatility has risen over the past four weeks, as traders react to the conflicting news coming from various governments and leaders in various economic sectors. This week, the Nasdaq Composite and the Dow Jones Industrial Average both entered correction territory (dropping more than 10% from recent highs).

If the conflict persists, the Fed's path narrows, not widens. The inevitable rise in inflation from a drawn-out conflict will force the Fed to raise interest rates rather than lower them to combat weakness in the jobs market. The worst-case scenario is the rise of stagflation, which makes the Fed's job that much harder.

This week, all international actors involved in the conflict have made peace claims and have expressed an intent to negotiate. Time will tell if what they say is happening actually happens. In the meantime, Brent Oil futures are trading around $110 a barrel as the week ends, with speculation that it could rise further.

How does this affect AI companies specifically? For an AI portfolio, this global turmoil creates three simultaneous pressures:

Higher energy costs for data centers Higher discount rates that crush long-duration growth stocks. Broad market volatility that compresses multiples on anything speculative. When all this drama happens, an investor's first instinct is to sell AI and buy oil majors, which oversimplifies the problem at hand. The better question is: Which AI-adjacent positions are structurally insulated from the macro pressures created by the conflict?

Here are two thoughts to consider:

1. Look at the physical infrastructure over software pricing. When the macro environment is unstable, the stocks that hold up best are those that already have physical capacity contracted. Modine Manufacturing (MOD 1.01%) is a good example of this, with a five-year backlog of data center cooling contracts. Hyperscalers don't stop needing cooling because oil went to $100 -- they've already signed the agreements. Modine's data center revenue grew 31% sequentially in Q3 fiscal 2026. That's a business being pulled by physical demand, not priced off sentiment.

Today's Change

(

-1.01

%) $

-2.19

Current Price

$

213.62

2. No debt allows you to be more patient. A company like Clearfield (CLFD 3.87%) is a strong example here. Clearfield carries zero debt and $157 million in cash. Rising interest rates don't squeeze a balance sheet that has none. The company's NOVA platform is being pulled into AI data center deployments by actual customer demand. If rates stay elevated because the Fed stays on hold, Clearfield's clean balance sheet is a genuine advantage over more leveraged players.

Today's Change

(

-3.87

%) $

-1.11

Current Price

$

27.60

There are AI portfolio holdings you might think about reducing The most exposed positions in an AI portfolio right now are speculative growth names with no earnings, high capital intensity for their next phase of growth, and valuations that depend on rate cuts arriving soon. The Fed has essentially told you those cuts aren't coming as long as the Strait of Hormuz situation persists.​

I'm also watching data center REITs carefully. They're capital-intensive, rate-sensitive, and now face rising energy input costs. For example, data center real estate investment trusts (REITs) like Equinix (EQIX 0.04%) and Digital Realty (DLR +0.47%) sit right in the AI buildout but still behave like old‑school, leveraged utilities when rates and power costs spike.

Today's Change

(

-0.04

%) $

-0.39

Current Price

$

963.00

It's time to get more selective about AI stocks You don't have to abandon AI stocks to protect your portfolio right now.

You do have to get more selective about which part of the AI stack you own. The physical layer (think cooling, fiber, and contracted enterprise tooling) has a different risk profile than speculative software or GPU-dependent pure plays.​

The war in the Middle East is a macroeconomic event. AI infrastructure buildout is a decade-long structural one. Invest in the physical layer during times like this.

333 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

23.38K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

In a long career of conquering huge manufacturing challenges, Elon Musk might have just undertaken his biggest challenge yet. Last week, he introduced Terafab.

Terafab marks Musk's latest in a long line of audacious bets, this time homing in on semiconductor production.

Fabricating leading-edge semiconductors is one of the most difficult manufacturing challenges in the world -- perhaps the most difficult. So why does Musk think he can pull it off? And how can investors gain exposure to this massive project?

Image source: Getty Images.

Terafab's goal: Produce a terawatt of compute Musk thinks he's going to need more chips. Lots more chips -- so much so that he will need to build his own massive fab to meet his needs.

Just how large are these needs? In the future, Musk envisions needing a terawatt of compute per year. To put that in perspective, Musk noted in his presentation that the world's current AI computing manufacturing capacity is just 20 gigawatts – roughly 2% of the capacity he says he will require. While leading fabs will no doubt greatly increase their AI chip capacity going forward, Musk doesn't believe it will be at a pace nearly fast enough to satisfy the demand he envisions. That's especially true given the widespread shortages of GPUs and CPUs today, and the fact that much of the world's current fab capacity is taken up by giants such as Nvidia and others.

While Tesla (TSLA 2.70%) is already making chips with Samsung, Musk noted in the Terafab presentation that major chip fabs don't like to expand too quickly. After all, the chip industry has been quite cyclical in the past, so chipmakers are reluctant to expand too much in any one year in case of an economic downturn. Samsung, for its part, has lagged market leader Taiwan Semiconductor Manufacturing (TSM +0.40%) in yields and efficiency. Samsung is also the world's largest memory company and will have to invest heavily in expanding both DRAM and NAND output, in addition to its logic semiconductors.

Given the intense competition for a limited supply, it's no wonder Musk is considering building his own fab.

What is Musk going to do with all those chips? Musk's two big companies, Tesla and the soon-to-be-public SpaceX, will be the primary users of the chips.

In Musk's presentation, he outlined a strong need for chips to power Tesla's robotaxi fleet; however, the demand will be much, much greater from Tesla's upcoming Optimus robots. While Tesla's AI chip needs will be robust, Musk predicts Optimus robots will require between 10 and 100 times that amount over time. Tesla plans to release the first Optimus robots in 2027, and Musk believes these robots could eventually outnumber humans.

But Musk believes Tesla and Optimus will account for only about 100 to 200 GW, or 10% to 20% of the terafab's capacity. So the majority of the remaining 800 GW or so will be for SpaceX's efforts. Of note, SpaceX just merged with Musk's AI company, xAI. While some of the remaining chip capacity may go to xAI's AI data centers here on earth, Musk actually intends to use the vast majority of the chipmaking capacity for space.

Not only will those ambitions include AI data centers in space -- an idea that has recently received a lot of media attention -- but Musk also outlined plans to build a space station on the moon to launch rockets to other planets. Launches from the moon would be less costly, according to Musk, because the moon doesn't have the gravitational pull of Earth. And Musk's vision isn't just for enterprises; he also sees a thriving consumer space economy, contemplating tourist trips to Saturn, among other futuristic visions.

Obviously, building an entire industrial AI-driven space economy would be a massive undertaking, and that is why Terafab will be required to meet those ambitions.

Today's Change

(

3.45

%) $

3.84

Current Price

$

115.24

2 ways to get exposure to the Terafab Having a Terafab is tantalizing for investors. After all, TSMC, the world's largest semiconductor foundry, is valued at $1.8 trillion. So if Terafab were 50 times the size of TSMC, would Terafab's value alone be $90 trillion?

Of course, Terafab might not be its own standalone company. The presentation indicates it will be co-owned and managed by Tesla, currently valued at $1.4 trillion, and SpaceX, which is rumored to be valued at $1.75 trillion ahead of its upcoming IPO.

SpaceX is set to go public soon, but for those looking to jump in on SpaceX before it goes public -- especially as it will consume the majority of Terafab's theoretical output -- EchoStar (SATS +3.45%) currently functions as a proxy for SpaceX stock. EchoStar was previously a declining satellite cable and wireless business, but it sold SpaceX valuable spectrum last summer, partially in exchange for SpaceX stock. Today, that stake in SpaceX accounts for the majority of EchoStar's market value.

So the two ways to "invest" in Terafab are currently Tesla and EchoStar, with SpaceX another option when it goes public.

But the Terfab vision seems pretty far-fetched right now It should be noted that Musk's vision seems a bit untethered from reality today, at least without significant technological breakthroughs.

Semiconductor manufacturing is perhaps the most challenging and capital-intensive endeavor on Earth, and it's becoming increasingly difficult as today's transistors shrink to atomic levels. Getting enough chip expertise to design, manufacture, test, and package a terawatt of compute at good yields would be a monumental undertaking. Merely assembling the chip design and manufacturing talent to accomplish this goal would be daunting, as Musk would have to poach the very best minds from all the other major fabs and chip designers.

But even beyond the talent challenges, the financial costs would also be enormous. For reference, TSMC had $117.4 billion in property, plant, and equipment at the end of 2025, and management forecasts capital spending of $52 billion to $56 billion in 2026 -- its highest-ever annual investment.

Theoretically, a Terafab producing 50 times the amount of chips TSMC makes would cost some $6 trillion in capital spending alone. Even assuming Musk finds some incredible way to produce chips twice as efficiently as the most efficient chip producer today, that would still be a $3 trillion investment. While SpaceX is rumored to be raising $75 billion in its upcoming IPO, that would account for only 2% or less of the required Terafab spending.

Needless to say, investors may want to exercise caution when factoring Terafab into these companies' valuations. There will be a lot of time and money spent between now and any sort of production or financial return.

Chewy (CHWY 3.29%) shares climbed after the company issued an upbeat outlook when it reported its fiscal Q4 earnings last week. Despite the gains, the stock of the pet products e-commerce operator is still down nearly 21% in 2026, and the stock looks like it has plenty of room to continue to rebound.

Let's take a closer look at Chewy's results and prospects and why the stock looks like a buy.

Image source: Getty Images.

Custom growth and strong outlook Chewy's fiscal Q4 itself was nothing to get too excited about, as the company grew its revenue by just 0.5% year over year to $3.26 billion, matching analyst expectations. Meanwhile, adjusted earnings per share of $0.27 came up a penny short of the consensus estimate.

However, its underlying metrics remained solid. Sales on a normalized 13-week basis were up 8.1%. It saw its active customers climb 4% year over year to 21.3 million, while net sales per active customer rose 2.2% to $591. Sales derived from autoship customers, meanwhile, jumped 4.8% to $2.74 billion and accounted for 84% of its total revenue.

Importantly, margins continued to expand. Its gross margin grew by 90 basis points to 29.4%, while its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margins climbed from 3.8% to 5%. This helped lead to a 30.4% increase in adjusted EBITDA to $162.3 million.

Margins are expected to continue to improve this year, with the company guiding for adjusted EBITDA margins to come in between 6.6% and 6.8%, about 100 basis points higher than fiscal 2025. The margin expansion will be led by increased private brand penetration, AI adoption, and the ramp-up of its new fulfillment center in Houston. The company also acquired a small, high-margin equine health business that it is looking to stabilize, and it continues to see solid momentum with high-margin sponsored ads.

Overall, it is looking for full-year revenue between $13.6 billion and $13.75 billion, representing growth of between 8% and 9%. It projected adjusted EBITDA between $900 million and over $930 million, good for growth of between 20% and 29%. This assumes that the pet industry as a whole sees low-single-digit growth, largely driven by volumes.

Today's Change

(

-3.29

%) $

-0.89

Current Price

$

26.12

A cheap stock with strong operating leverage What makes Chewy an attractive stock is that the company has a steady, visible business anchored by its autoship customers. That is highly valuable, and these types of companies typically trade at premium valuations because they are great compounding businesses. Meanwhile, Chewy is doing a great job of delivering high-single-digit sales growth and expanding its margins.

Despite that, the stock trades at a forward P/E of just 17 times current-year analyst estimates and 14 times next year's consensus. That is just way too low for this type of business, and the stock has a lot of upside from here in my view.

Shares of CrowdStrike Holdings (CRWD 5.77%) have shed more than a third of their value since hitting an all-time high in November. A lot of high-growth tech stocks have stumbled in recent months, but CrowdStrike and most of its cybersecurity peers have come under laser-focused bearish selling pressure since late February.

Many publicly traded software-as-a-service companies (SaaS stocks) have been suffering since January. The release of agentic AI tools -- along with the potential for more powerful solutions down the line -- poses a challenge to enterprise software companies. If their clients can automate tasks with fewer licenses or modules, many SaaS leaders can stumble as a chunk of their client budgets go elsewhere.

Image source: Getty Images.

Cybersecurity stocks were initially spared the brunt of the malaise, but the narrative turned bearish late last month, after Anthropic's Claude coding model previewed a new security tool. Suddenly, CrowdStrike and its industry-leading Falcon endpoint security platform became vulnerable. If Falcon's specialty of protecting a company's devices from breaches can be done effectively at a lower price point, wouldn't CrowdStrike be in for a world of hurt?

That's not an easy question to answer, but largely because it's an unfair question to ask. There isn't a CrowdStrike killer on the market right now. CrowdStrike has served its clients well, and the cloud-based platform operator has consistently delivered top-line growth north of 20% or better. In a potential plot twist, the agentic AI revolution offers a higher ceiling rather than a lower floor for CrowdStrike investors.

Let's use these Falcon wings to swoop a little closer.

Today's Change

(

-5.77

%) $

-22.64

Current Price

$

369.98

Birds of prey I wasn't a CrowdStrike bear before. I've been an investor for years. However, it remains one of my smaller positions. The stock's sharp correction over the past four months hasn't been a dinner bell. It's been more of an alarm. Bullish exclamation points have turned into concerned question marks about its future. However, a look at its past offers insight into its future.

CrowdStrike's AI-native security solutions are popular for a reason: They work. Engagement has only increased as customers who trust CrowdStrike rely on more of its offerings, which now include 33 modules. A year ago, 21% of its customers were paying for at least eight CrowdStrike modules. Today, the penetration rate is up to 24%. Revenue rose 22% last year, making it at least the eighth consecutive year of decelerating top-line growth. However, guidance it initiated earlier this month for the new fiscal year calls for a 22% to 23% increase.

Why is CrowdStrike's business growing, and potentially accelerating for the first time as a public company in the new fiscal year, if the agentic AI revolution is a bigger threat than an opportunity? I'm not buying the bearish narrative. The growing adoption of agentic AI will only heighten client demand for CrowdStrike's services, if only because it raises the stakes on the need to keep their platforms secure.

Will businesses really trust AI startups with the keys to the gate protecting the loyalty they can't afford to squander? I have been nervous as a small CrowdStrike investor amid the recent decline. I'm starting to get excited about the situation.

A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake Purchase Licensing Rights, opens new tab

March 29 (Reuters) - Eli Lilly (LLY.N), opens new tab will sign ​a $2 billion deal ‌with Hong Kong-listed biotech Insilico ​Medicine (3696.HK), opens new tab, which ​uses artificial intelligence ⁠for drug ​discovery, the Financial ​Times reported on Sunday.

Lilly will acquire ​exclusive rights ​to sell a GLP-1 ‌drug ⁠for diabetes from Insilico Medicine, the FT ​report ​said, ⁠citing sources familiar with ​the matter.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Reuters ​could ⁠not immediately verify the report.

Reporting ⁠by ​Rishabh ​Jaiswal in Bengaluru. Editing ​by Mark Potter

Our Standards: The Thomson Reuters Trust Principles., opens new tab

CompaniesSEOUL, March 29 (Reuters) - Workers at Samsung Biologics (207940.KS), opens new tab have ​voted in favour of ‌authorising strike action, paving the way for ​the first strike ​in the company's history, local ⁠media reported on ​Sunday.

According to the reports, ​which cited the union, 95.38% of eligible voters took ​part in the ​ballot, with 95.52% voting in ‌favour. ⁠The union has 3,689 members, accounting for about 75% of ​the company’s ​workforce, ⁠the reports said.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

The union plans ​to continue informal ​discussions ⁠with management before deciding whether to proceed ⁠with ​a strike, the ​reports added.

Reporting by Kyu-seok Shim. ​Editing by Mark Potter

Our Standards: The Thomson Reuters Trust Principles., opens new tab

LOS ANGELES--(BUSINESS WIRE)---- $IBRX--ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – IBRX.

12.01K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The article is for informational purposes only (not a solicitation or recommendation to buy or sell stocks). David is not a registered investment adviser. Investors should do their own research or consult a financial adviser to determine what investments are appropriate for their individual situation. This article expresses my opinions, and I cannot guarantee that the information/results will be accurate. Investing in stocks involves risk and could result in losses.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

23.55K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Rexford Industrial Realty now trades at a 5.36% yield and a historically low valuation, reflecting rebased growth expectations. REXR's AFFO growth is forecast at just 1.66% annually through 2028, with recent results confirming anemic expansion and management guiding for a core FFO decline. Capital allocation is a concern, as REXR is funding share buybacks with asset sales, signaling limited reinvestment opportunities and potential business shrinkage.

Ontology (ONT) moved into the ‘extreme greed’ zone on local crypto sentiment gauges on Sunday ET, a signal that short-term positioning may be overheating even as the token pulled back from an intraday spike.

ONT was trading around 93.2 won per token, down 3.52% day over day, after briefly touching 99.0 won earlier in the session. The day’s range was wide—roughly 90.1 won to 99.0 won—highlighting rising volatility following a rapid run-up and subsequent profit-taking.

Market attention has centered on the coin’s fear-and-greed reading, where ONT/KRW ranked first with a score of 90, placing it firmly in ‘extreme greed’. While still elevated, the sentiment score reportedly fell by 6 points on the day, suggesting the intensity of the overheating may be moderating at the margin.

Chiliz (CHZ) followed with a reading of 72 (‘greed’), while Akash Network (AKT), JUST (JST), and Steem (STEEM) clustered near the mid-to-high 50s, a ‘neutral’ band that typically implies more balanced positioning. On the opposite end of the spectrum, several smaller-cap names registered ‘extreme fear’, led by NominA (NOM) at 8, alongside Lombard (BARD) at 11, Kite (KITE) at 14, Sign (SIGN) at 16, and Worldcoin (WLD) at 22. Many of those fear readings edged higher on the day, but remained depressed overall—consistent with ongoing risk aversion in those tokens.

On-chain metrics were not cited, but trading activity on the KRW market pointed to aggressive short-term participation. ONT’s 24-hour volume reached about 794.6 million tokens, with turnover valued at roughly 75.4 billion won. Such surges in traded value often accompany momentum-driven runs, and can amplify both upside breakouts and abrupt pullbacks as leveraged and fast-money flows rotate.

Broadly, KRW majors were modestly firmer, with Bitcoin (BTC) up about 0.44% to 101,335,000 won and Ethereum (ETH) up 0.53% to 3,047,000 won. XRP (XRP), Solana (SOL), and Dogecoin (DOGE) also posted small gains, reflecting a mixed but not risk-off tone across large caps. Against that backdrop, ONT underperformed, while NOM slid sharply by around 10%. Steem (STEEM) stood out on the upside, up nearly 6%, and Vana (VANA) gained more than 12%.

The combination of a top-ranked ‘extreme greed’ reading and a same-day reversal from 99.0 won to the low 90s underscores a market wrestling with stretched near-term positioning. With liquidity concentrated and price swings widening, traders will be watching whether ONT can retest the 99.0 won high, and whether support near 90.1 won holds as the market digests the spike in turnover.

Article Summary by TokenPost.ai

🔎 Market Interpretation

Sentiment overheated: Ontology (ONT) entered the ‘extreme greed’ zone with a fear-and-greed score of 90 (ranked #1 in ONT/KRW), typically signaling crowded short-term longs and higher reversal risk.

Reversal alongside greed reading: Despite the euphoric sentiment, ONT pulled back to ~93.2 KRW (-3.52% DoD) after an intraday spike to 99.0 KRW, suggesting profit-taking into strength.

Volatility expanded: The session range (~90.1–99.0 KRW) indicates widening swings often seen after sharp momentum moves, increasing both breakout potential and drawdown risk.

Greed cooling slightly: The sentiment score reportedly fell 6 points on the day, hinting that the most excessive positioning may be easing, though still at an extreme level.

Broader market not risk-off: Large-cap KRW pairs were modestly higher (BTC +0.44%, ETH +0.53%), implying ONT’s weakness is more idiosyncratic/momentum-related than driven by a broad market dump.

Fear pockets remain: Smaller caps showed ‘extreme fear’ (e.g., NOM 8), reflecting selective risk aversion outside the day’s momentum leaders.

💡 Strategic Points

Key levels in focus: Traders are watching 99.0 KRW as near-term resistance (failed spike high) and ~90.1 KRW as immediate support (session low). A break of either side could accelerate follow-through.

Volume suggests fast-money participation: ONT’s ~794.6M tokens traded (~75.4B KRW turnover) aligns with a momentum-driven phase where moves can become self-reinforcing—and reversals can be abrupt.

Overcrowding risk management: An ‘extreme greed’ reading combined with a same-day pullback often warrants tighter risk controls (e.g., reduced sizing, defined invalidation near support, or waiting for consolidation).

Scenario mapping:

Bull case: Price stabilizes above ~90 KRW, volume normalizes, and ONT retests 99 KRW with a cleaner structure.

Bear case: Support near 90.1 KRW fails, triggering momentum unwind as late buyers exit and volatility remains elevated.

Relative performance watch: ONT underperformed while some alts (e.g., STEEM, VANA) gained, suggesting rotation within KRW alts—useful for gauging whether ONT’s move was a one-off spike or part of a broader sector bid.

📘 Glossary

Fear-and-Greed Index (local sentiment gauge): A score that approximates market mood/positioning; higher values imply optimism and potential crowding, lower values indicate fear and risk aversion.

Extreme Greed: A very high sentiment reading (here, 90) often associated with overheated positioning and increased probability of pullbacks or whipsaws.

Intraday spike: A sharp price move within a single trading session that may reverse if buying is exhausted.

Day’s range: The difference between the session high and low; widening ranges generally indicate rising volatility.

Turnover (traded value): The notional value traded over a period (e.g., 24h). High turnover can amplify price moves due to rapid flow and short-term speculation.

Profit-taking: Selling after a rapid rise to lock in gains, commonly causing pullbacks after spikes.

Support / Resistance: Price zones where buying (support) or selling (resistance) tends to emerge, influencing short-term direction.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Cardano is currently trading at a price level that is crucial for its price action. At the time of writing, ADA was trading down 0.76% in the last 24 hours to $0.245 as the broader crypto market saw dull price action over the weekend.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

While part of the crypto community is becoming increasingly convinced this weekend that a deep correction is coming for XRP, relying in part on technical patterns across crypto charts, other indicators — particularly on the daily XRP/USD chart on TradingView — are beginning to suggest the exact opposite. The bearish scenario of a 30% drop below the $1 level for XRP may turn out to be more of a bear trap than an inevitability.

Popular analysts, including Ali Martinez, have recently emphasized XRP’s weakness, pointing to a potential decline toward $0.95. However, these conclusions are largely based on the four-hour time frame and a triangle pattern, which XRP has broken below.

Why analysts predicting 30% XRP price drop could be wrongA closer look at the daily time frame reveals that buyer strength is still present, though hidden within the current consolidation phase. According to the volume profile, the main trading activity — the point of control — sits within the $1.37-$1.45 range. The current price of $1.33 is slightly below this major volume block, which in classical technical analysis is often interpreted as a false breakdown designed to collect liquidity before a reversal.

HOT Stories

If XRP were truly preparing for a 30% drop, it would have already moved quickly through this zone without resistance. Instead, the ongoing accumulation suggests that large players are holding prices while absorbing sell pressure.

XRP/USD Daily Chart, Source: TradingViewAt the same time, the Relative Strength Index on the daily chart is sending a bullish signal too. While XRP price printed lower lows in February and March, RSI formed higher lows. This bullish divergence is one of the most important leading indicators, signaling that bearish pressure is fading and the market may be preparing for an upward move.

You Might Also Like

The accumulation of volume combined with the RSI signal suggests that XRP is in the final stage of a shakeout before the start of a new bullish cycle. The key moment will be the close of the March candle. If XRP holds above $1.37, the bearish scenario outlined by Martinez and other skeptics may be invalidated.

Sun, 29/03/2026 - 10:21

Adam Back identifies an "abnormal" surge in Bitfinex margin longs, hitting an ATH of 79,000 BTC. As of March 29, 2026, whales are deploying $20 million daily in tactical TWAP buys below $69,000.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

While crypto market participants have switched into macroeconomic and geopolitical analysts, keeping their focus on the oil chart, a different scenario is unfolding on Bitfinex — one that industry legend Adam Back highlights as unprecedented.

According to the latest margin position monitoring data, the volume of long positions on Bitfinex has now reached a historical high not seen since November 2023, hitting 79,193 BTC.

Adam Back explains why this Bitfinex accumulation is "unprecedented"The CEO of Blockstream pointed out a unique market structure. In particular, a group of institutional players appears to be using a TWAP strategy — time-weighted average price — aggressively buying up any available supply below the $69,000 level.

HOT Stories

As Back emphasizes, margin holding on Bitfinex has been accelerating since late 2020. Around 79,000 BTC have been accumulated using leverage, with an estimated build rate of 300 BTC or more per day through organic trades.

Based on these calculations, the intensity of accumulation translates into approximately $20 million flowing into Bitcoin daily, about $14,000 spent every minute, around the clock — averaging between 450 and 600 BTC purchased.

What makes the current situation notable is that this accumulation is happening during a correction phase. While retail participants remain cautious, large players on Bitfinex are demonstrating conviction. Back stresses that this is not artificial speculation, but rather a long-term strategic positioning by entities that are difficult to identify.

You Might Also Like

At present, the broader market shows signs of bearish exhaustion on the weekly time frame. According to some analysts, including Back, the sheer size of accumulated positions could lead to a liquidity shortage on the supply side.

If the current pace of $14,000 per minute in buying pressure continues, any positive catalyst could accelerate price movement sharply, as available supply in the market depth has already been reduced. If this framework holds, the market may be witnessing a redistribution of assets from weaker hands to strategic accumulators.

The Bitcoin market on Bitfinex is now, in this context, emerging as a leading indicator for the broader crypto market.

Related articles